
I-Mab IMAB
Quarterly report 2025-Q2
added 01-31-2026
I-Mab DPO Ratio 2011-2026 | IMAB
Annual DPO Ratio I-Mab
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | 2.24 K | - | - | - | - | - | - | - | - | - | - |
All numbers in CNY currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2.24 K | 2.24 K | 2.24 K |
DPO Ratio of other stocks in the Biotechnology industry
| Issuer | DPO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Alexion Pharmaceuticals, Inc.
ALXN
|
78.2 | - | - | $ 40.3 B | ||
|
Midatech Pharma plc
MTP
|
162 | - | -18.52 % | $ 27.3 M | ||
|
Acorda Therapeutics
ACOR
|
277 | - | -24.86 % | $ 820 K | ||
|
Acasti Pharma
ACST
|
4.39 K | - | 4.01 % | $ 150 M | ||
|
Akebia Therapeutics
AKBA
|
80.4 | $ 1.42 | -2.07 % | $ 266 M | ||
|
Albireo Pharma
ALBO
|
1.59 K | - | -0.23 % | $ 916 M | ||
|
Институт стволовых клеток человека
ISKJ
|
115 | - | - | - | ||
|
Amgen
AMGN
|
49.6 | $ 342.65 | -0.08 % | $ 184 B | ||
|
Ampio Pharmaceuticals
AMPE
|
2.85 K | - | -11.43 % | $ 502 K | ||
|
ANI Pharmaceuticals
ANIP
|
60.1 | $ 81.6 | -0.49 % | $ 1.58 B | ||
|
Aeterna Zentaris
AEZS
|
34.4 K | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
9.04 K | - | -10.17 % | $ 12.2 K | ||
|
Aytu BioScience
AYTU
|
186 | $ 2.63 | 1.74 % | $ 16.5 M | ||
|
Brickell Biotech
BBI
|
105 | - | -5.38 % | $ 6.06 M | ||
|
Amneal Pharmaceuticals
AMRX
|
21.1 | $ 13.65 | -3.3 % | $ 4.22 B | ||
|
AIkido Pharma
AIKI
|
32.8 K | - | 1.93 % | $ 17.4 M | ||
|
BioCryst Pharmaceuticals
BCRX
|
484 | $ 6.58 | -1.35 % | $ 1.36 B | ||
|
BeiGene, Ltd.
BGNE
|
915 | - | 0.49 % | $ 251 B | ||
|
Biogen
BIIB
|
65.4 | $ 178.24 | 1.2 % | $ 26 B | ||
|
Ayala Pharmaceuticals
AYLA
|
2.21 K | - | - | $ 7.46 M |